FDA's top generic drug leader puts in her two weeks as GDUFA III looms
The FDA is about to lose another top leader with the departure of Sally Choe, director of the FDA’s Office of Generic Drugs, on Oct. 8. The departure coincides with the transition from the second reauthorization of the Generic Drug User Fee Amendments to the third reauthorization, which Congress has until Friday to finish up.
Choe, who didn’t immediately say where she’s heading post-FDA, but did a stint at Parexel, has served as the OGD director since February 2019, and “has been the principal medical and technical authority on all matters related to generic drug review and advised me and other agency officials,” CDER director Patrizia Cavazzoni said in an email to staff announcing Choe’s departure.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.